Gonul Hazal Koc

Gonul Hazal Koc

Auto-generated profile, based on publicly available information

Gonul Hazal Koc

Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGonul Hazal Koc
Gonul Hazal Koc
ALAgnes E.M. Looijen
Agnes E.M. Looijen
IHIrene E. van der Horst-Bruinsma
Irene E. van der Horst-Bruinsma
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objective: The disease course and burden of rheumatoid arthritis (RA) may differ between female and male individuals, but existing data on these differences are limited and often contradictory. Therefore, we investigated whether clinical outcomes and patient-reported outcomes (PROs) differ between female and male patients with RA over time. Methods: All female (n = 286) and male (n = 139) patients with RA according to 1987 and/or 2010 criteria from Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a stratified single-blinded trial with a treat-to-target (T2T) approach and fixed medication protocol, were included. Clinical outcomes include disease activity, medication usage, sustained disease-modifying antirheumatic drug (DMARD)-free remission (SDFR), and radiographic progression. In addition, the following PROs were investigated: general health, pain, functional ability, health-related quality of life, fatigue, productivity loss, and a possible depression or anxiety disorder. For comparisons over time, a mixed model or Cox proportional hazard model was used. The mixed models were adjusted for age, initial treatment, and disease activity (Disease Activity Score in 44 joints [DAS44]). Results: Female patients had a higher DAS44 over time compared to male patients (β 0.36, 95% CI 0.25-0.47, P < 0.001), which also resulted in more treatment adjustments including use of biologic DMARDs (bDMARDs; 36% vs 24%, P < 0.001). Although not significant, first bDMARD survival seemed shorter in female patients (hazard ratio [HR] 1.4, 95% CI 0.8-2.6, P = 0.24). However, no differences were found in SDFR and radiographic progression. With regard to PROs, only functional ability differed significantly between sexes after adjusting for confounders, including disease activity (Health Assessment Questionnaire–Disability Index, β 0.10, 95% CI 0.04-0.17, P < 0.001). Conclusion: Clinical outcomes and PROs are intertwined, and both improve with a T2T management approach. Nevertheless, female patients with RA have higher disease activity, a greater need for bDMARDs—although these have lower efficacy—and more functional impairment over time, underscoring the need for sex-specific management recommendations. (Trial registration number: ISRCTN26791028 )

6 November 2024 in Rheumatology
Verified
Journal Article
Open access
PDF file
SHSelinde V J Snoeck Henkemans
Selinde V J Snoeck Henkemans
MVMarijn Vis
Marijn Vis
GKGonul Hazal Koc
Gonul Hazal Koc
JLJolanda J Luime
Jolanda J Luime
MKM.R. Kok
M.R. Kok
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objectives: To investigate the association between depression and anxiety and the inability to achieve remission in RA and PsA patients. In addition, the association between depressive and anxiety symptoms and disease activity components was explored. Methods: A total of 400 RA and 367 PsA patients from the tREACH and DEPAR were included, respectively. Patients had a possible depression or anxiety disorder if they scored >7 on the Hospital Anxiety and Depression Scale (HADS). Remission was defined as DAS44 <1.6 in RA and DAPSA ≤ 4 in PsA. Mixed models were used to assess the association between depression/anxiety, at any timepoint during 2 years, and remission during 2 years, and to explore which disease activity components are most influenced by depression/anxiety. Results: At baseline, 20% of RA patients had a possible depression and 30% a possible anxiety disorder. In PsA this was 18% and 23%. After adjustment for concurrent anxiety symptoms, depression was associated with a lower odds of achieving remission during 2 years of follow-up [OR 0.45 (95%CI 0.25–0.80) for RA and OR 0.24 (95%CI 0.08–0.71) for PsA]. Anxiety was not associated with remission after adjustment for concurrent depression symptoms. The presence of depression/anxiety was associated with higher tender joint count, worse general health, more pain and slightly elevated inflammation markers, but not with more swollen joints in both RA and PsA. Conclusion: The presence of depressive symptoms in RA and PsA patients at baseline or during follow-up was associated with a lower likelihood of achieving remission. Healthcare professionals should, therefore, be aware of symptoms of depression.

24 May 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
GKGonul Hazal Koc
Gonul Hazal Koc
MKM.R. Kok
M.R. Kok
YRYvandra Do Rosario
Yvandra Do Rosario
JLJolanda J. Luime
Jolanda J. Luime
ITIlja Tchetverikov
Ilja Tchetverikov
MVMarijn Vis
Marijn Vis
Objective Persistent articular inflammation in psoriatic arthritis (PsA) is associated with radiographic damage. Despite advances in diagnosis and therapy, radiographic structural damage remains prevalent in PsA. To elucidate this topic, we studied which baseline clinical characteristics determine radiographic progression. Methods For this analysis, data were used from DEPAR (Dutch South West Psoriatic Arthritis) Study, a real-world cohort of patients with newly diagnosed PsA. Radiographic changes were assessed using the modified Total Sharp/van der Heijde Score (mTSS) for PsA. Univariable–multivariable mixed-effects negative binomial regression analysis was applied to define baseline predictors for radiographic progression over time. Results The study included 476 patients with early PsA with 1660 hand and feet radiographs from four different time points (baseline, first, second and third year). The progressive group (n=71) had a higher mTSS compared with the non-progressive group (n=405) at diagnosis (17 (3–36) vs 0 (0–1)). A comparison of the two groups revealed that the progressive group had significantly older (59 (12) vs 49 (13)) and a higher rate of the presence of swollen joints (93% vs 78%) at diagnosis. Multivariable analysis identified age (incidence rate ratio (IRR)=1.10, p=0.000), sex (female) (IRR=0.48, p=0.043) and baseline mTSS (IRR=1.11, p=0.000) as significant determinants of radiographic change over time. For the progressive subset, additionally, the multivariable analysis highlighted baseline Disease Activity in PSoriatic Arthritis (IRR=1.05, p=0.006) and swollen joint count (IRR=1.07, p=0.034) as predictors. Conclusions According to this real-world cohort, patients with early PsA exhibit minimal radiographic progression under current treatment protocols. This study indicates that while old age and initial radiographic damage predict progression, female sex confers a protective effect on it. Furthermore, disease activity score and swollen joints emerged as predictors for radiographic changes during the follow-up in progressive patients.

18 October 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
ALAgnes E.M. Looijen
Agnes E.M. Looijen
SHSelinde V J Snoeck Henkemans
Selinde V J Snoeck Henkemans
AMAnnette H M van der Helm-Van Mil
Annette H M van der Helm-Van Mil
PWPaco M J Welsing
Paco M J Welsing
GKGonul Hazal Koc
Gonul Hazal Koc
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presenteeism (0%–100% productivity loss) could aid as a screening tool to detect active disease in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods RA patients from the tREACH trial and TARA trial (n=683) and PsA patients from the DEPAR cohort (n=525) were included. The association of a deterioration in the aforementioned patient-reported outcome measure (PROM) scores between two consecutive visits and having active disease was assessed. Active disease was defined as a change from disease activity score (DAS) ≤2.4 to DAS >2.4 in RA or Disease Activity Index in Psoriatic Arthritis (DAPSA) ≤14 to DAPSA >14 in PsA. The area under the curve (AUC) of the sum score of deteriorated PROMs was evaluated. Results 4594 RA and 1154 PsA visits were evaluated and active disease occurred in 358 (8%) RA and 177 (15%) PsA visits. In both RA and PsA, a deterioration in general health (VAS), HAQ-DI, EQ-5D and pain (VAS/NRS) was significantly associated with active disease. The combination of these PROMs showed acceptable to excellent discriminative ability (RA AUC=0.76, PsA AUC=0.85). If a cut-point of ≥1 deteriorated PROMs is used, 40% of the visits in which RA patients have remission or low disease activity are correctly specified (specificity of 40%), while 10% of visits with active disease are overlooked (sensitivity of 90%). In PsA, these percentages are 41% and 4%, respectively. Conclusion A combination of general health, HAQ-DI, EQ-5D and pain could aid as a screening tool for active disease in patients with RA and PsA. These data could help facilitate remote monitoring of RA and PsA patients in the future. Trial registration numbers ISRCTN26791028, NTR2754.


16 May 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
SHSelinde V.J. Snoeck Henkemans
Selinde V.J. Snoeck Henkemans
MVMarijn Vis
Marijn Vis
GKGonul Hazal Koc
Gonul Hazal Koc
JLJolanda J. Luime
Jolanda J. Luime
MKM.R. Kok
M.R. Kok
PJPascal Hendrik Pieter De Jong
Pascal Hendrik Pieter De Jong
According to current management guidelines for psoriatic arthritis (PsA) tapering of disease-modifying antirheumatic drugs (DMARDs) can be considered. However, limited data are available on complete DMARD cessation, also known as disease-modifying antirheumatic drug-free remission (DFR). Therefore, our aim was to investigate whether DFR is achievable and sustainable in PsA and to evaluate possible predictors for sustained disease-modifying antirheumatic drug-free remission (SDFR). From the Dutch southwest Early Psoriatic Arthritis cohort, all newly diagnosed patients with oligoarticular/polyarticular PsA who were treated with DMARDs were included (n = 451). Prevalence of (S)DFR and flare rates (early and late) were described. DFR was defined as the absence of clinical synovitis for ≥3 months after DMARD cessation, while for SDFR, a period of >1 year was used. Early and late flares were defined as restarting DMARD treatment ≤1 and >1 year after DMARD cessation, respectively. Subsequently, possible predictors for true SDFR, that is, SDFR without flaring were explored. After a median of 5.1 years (IQR, 3.0-7.3 years), 22% of patients with PsA had reached DFR, and after reaching DFR, 4.7% had an early flare. Thus, SDFR was achieved in 14.4% of patients with PsA; 5.3% experienced a late flare, which occurred a median of 1.7 years (IQR, 1.4-2.8 years) after DMARD cessation. Eventually, 9.1% of patients reached true SDFR. Low baseline Disease Activity Index in Psoriatic Arthritis and never using biological or targeted synthetic DMARDs were independent predictors for true SDFR. At the time of true SDFR, the Health Assessment Questionnaire was similar to the general population (median, 0.12; IQR, 0-0.75). DFR is attainable in oligoarticular/polyarticular PsA and is sustainable in 9% of patients. However, the subgroup of patients with PsA with high disease activity at baseline and who require biological or targeted synthetic DMARDs do not achieve true SDFR. To our knowledge, this is the first study to demonstrate that chronicity can potentially be influenced in a proportion of patients with PsA.